Welcome to our dedicated page for Oncocyte Corporation news (Ticker: OCX), a resource for investors and traders seeking the latest updates and insights on Oncocyte Corporation stock.
Oncocyte Corp. (Nasdaq: OCX) is a diagnostics technology company focused on molecular tests for organ transplantation and oncology, and its news flow reflects this dual focus. Company updates frequently describe progress toward commercializing a dd-cfDNA-based transplant rejection monitoring test kit, including clinical trial milestones, regulatory interactions, and reimbursement developments. Oncocyte also reports on the use of its proprietary assays in peer-reviewed studies and collaborations with leading transplant centers and research institutions.
Investors and clinicians following OCX news can expect regular announcements about the GraftAssure transplant portfolio, which includes the GraftAssureCore lab-developed test, the GraftAssureIQ research-use-only kit, and the planned GraftAssureDx in-vitro diagnostic kit. Recent releases have highlighted Medicare reimbursement improvements for the company’s lab-developed transplant assay, expanded coverage for specific high-risk patient groups, and adoption of GraftAssure research kits by transplant centers in the United States, Europe, and Southeast Asia.
Oncocyte’s news also covers scientific publications that use its proprietary assays to study transplant biology, such as data in Transplantation Direct examining dd-cfDNA levels and kidney allograft biopsies. In oncology, updates have discussed the role of the DetermaIO gene expression test in studies like NeoTRIP in triple negative breast cancer, as well as the DetermaCNI blood-based monitoring tool.
In addition, OCX news items report on quarterly and annual financial results, pharma services revenue from its CLIA-certified Nashville lab, capital raises, and its strategic partnership with Bio-Rad Laboratories. Corporate communications may also include participation in healthcare and diagnostics conferences and plans related to corporate renaming. For those tracking the company, the news stream provides insight into clinical, regulatory, scientific, and capital markets developments affecting Oncocyte’s transplant and oncology diagnostics programs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Oncocyte Corporation (OCX)?
What is the market cap of Oncocyte Corporation (OCX)?
